|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
gptkb:cream
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:available_on
|
prescription medication
|
|
gptkbp:brand
|
gptkb:Latisse
gptkb:Lumigan
|
|
gptkbp:casnumber
|
162410-64-8
|
|
gptkbp:chemical_formula
|
C25 H37 N2 O4 S
|
|
gptkbp:class
|
synthetic prostaglandin analog
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
treatment of open-angle glaucoma
treatment of eyelash hypotrichosis
|
|
gptkbp:contraindication
|
hypersensitivity to bimatoprost
active intraocular inflammation
history of macular edema
history of uveitis
|
|
gptkbp:developed_by
|
gptkb:Allergan
|
|
gptkbp:formulation
|
0.01% solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bimatoprost
|
|
gptkbp:ingredients
|
gptkb:bimatoprost
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:marketed_as
|
gptkb:Latisse
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkb:Lumigan
|
|
gptkbp:mechanism_of_action
|
prostaglandin analog
|
|
gptkbp:pharmacokinetics
|
metabolized in the liver
increases aqueous humor outflow
reduces intraocular pressure
highly lipophilic
|
|
gptkbp:related_products
|
gptkb:travoprost
gptkb:latanoprost
unoprostone
|
|
gptkbp:research_areas
|
pharmacology
ophthalmology
cosmetic dermatology
|
|
gptkbp:route_of_administration
|
topical
|
|
gptkbp:shelf_life
|
check packaging
|
|
gptkbp:side_effect
|
fatigue
headache
dry eyes
skin rash
eye irritation
conjunctival hyperemia
changes in eyelash color
increased brown pigmentation of the iris
|
|
gptkbp:storage
|
store at room temperature
protect from light
|
|
gptkbp:trade
|
gptkb:Latisse
gptkb:Lumigan
|
|
gptkbp:used_for
|
gptkb:Ophthalmology
gptkb:ocular_hypertension
eyelash growth
|
|
gptkbp:bfsParent
|
gptkb:Latisse
|
|
gptkbp:bfsLayer
|
6
|